Evidence in breast cancer patients has shown that sodium butyrate has a promising anti-tumor activity on breast cancer cells alone or in combination with other anti-cancer agents [49,50,51,52,53], for example, the anti-HER2 antibody trastuzumab [54]. This evidence concerns the gene ERBB2 and breast carcinoma.